In a phase II study of T-DM1 in relapsed HER2-positive NSCLC (IHC 3+, IHC 2+/FISH+, or exon 20 mutations), among fifteen assessable patients, only one patient achieved a PR (ORR=6.7%). Here, ERBB2 is linked to non-small cell lung carcinoma.